Brief: Theseus Pharmaceuticals Announces BCR-ABL as Target for Third Development Program
05/01/2023 12:08
Jan 5 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS- PRELIM DOSE-ESCALATION DATA
ANTICIPATED
IN Q2 2023 WITH ADDITIONAL DATA EXPECTED IN Q4 2023 FOR PHASE
1/2 TRIAL OF THE-630
* THESEUS PHARMACEUTICALS INC - IND SUBMISSION FOR 4G EGFR
INHIBITOR -349 EXPECTED IN Q4 2023
* THESEUS PHARMA-INTRODUCING BCR-ABL AS TARGET FOR THIRD
PROGRAM,
IN DEVELOPMENT FOR CML & PH+ ALL; SEES DEVELOPMENT CANDIDATE
NOMINATION BY EARLY 2024
Source text for Eikon: ID:nPnbxYFlna
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7